DMP1 and acute myeloid leukemia: Using an in vivo system specific to assess the osteogenic potential, AML-MSCs exhibited a reduced mature bone formation capacity and developed an osteoprogenitor-rich niche with the presence of osterix+/osteocalcin—pre-OBs and osteocalcin+/Dentin matrix acid phosphoprotein 1 (DMP1)—immature osteocytes [154].